Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates

分组1 - Pfizer reported quarterly earnings of $0.66 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.63 per share a year ago, resulting in an earnings surprise of +16.81% [1] - The company achieved revenues of $17.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.26%, although this represents a decline from year-ago revenues of $17.76 billion [2] - Pfizer has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 7.1% since the beginning of the year, outperforming the S&P 500, which has gained 1.9% [3] - The future performance of Pfizer's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.75 on revenues of $13.9 billion, and for the current fiscal year, it is $2.97 on revenues of $60.81 billion [7] 分组3 - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The Zacks Rank for Pfizer is currently 5 (Strong Sell), suggesting that the stock is expected to underperform the market in the near future [6]